AKR1C3

Oddi ar Wicipedia
Jump to navigation Jump to search
AKR1C3
Protein AKR1C3 PDB 1ry0.png
Strwythurau
PDBOrthologau:PDBe RCSB
Dynodwyr
CyfenwauAKR1C3, DD3, DDX, HA1753, HAKRB, HAKRe, HSD17B5, PGFS, hluPGFS, aldo-keto reductase family 1, member C3, aldo-keto reductase family 1 member C3
Dynodwyr allanolOMIM: 603966 MGI: 2145420 HomoloGene: 128661 GeneCards: AKR1C3
EC number1.3.1.20
Patrwm RNA pattern
PBB GE AKR1C3 209160 at fs.png

PBB GE AKR1C1 211653 x at fs.png
Rhagor o gyfeiriadau
Orthologau
SpeciesBod dynolLlygoden
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_003739
NM_001253908
NM_001253909

NM_134066
NM_001346535

RefSeq (protein)

NP_001240837
NP_001240838
NP_003730

NP_001333464
NP_598827

Lleoliad (UCSC)n/aChr : 4.13 – 4.15 Mb
PubMed search[2][3]
Wicidata
Gweld/Golygu Bod dynolGweld/Golygu Llygoden

Protein sy'n cael ei godio yn y corff dynol gan y genyn AKR1C3 yw AKR1C3 a elwir hefyd yn Aldo-keto reductase family 1 member C3 (Saesneg). Segment o DNA yw'r genyn, sy'n amgodio ffwythiant arbennig. Mae'r genyn yma wedi ei leoli ar yr edefyn blaen o gromosom dynol 10, band 10p15.1.[4]

Cyfystyron[golygu | golygu cod y dudalen]

Yn aml mae gan enynnau lawer o gyfystyron. Mae hyn oherwydd eu bod yn aml yn cael eu darganfod gan nifer o bobl mewn cyd-destunau gwahanol heb wybod mai'r un genynnau oeddyn nhw. Hefyd mae gan wahanol gymunedau gwyddonol safonau gwahanol ar gyfer enwi genynnau. Dyma restr o gyfystyron ar gyfer y genyn AKR1C3.

  • DD3
  • DDX
  • PGFS
  • HAKRB
  • HAKRe
  • HA1753
  • HSD17B5
  • hluPGFS

Llyfryddiaeth[golygu | golygu cod y dudalen]

  • "Association of AKR1C3 Polymorphisms with Bladder Cancer. ". Urol J. 2016. PMID 27085562.
  • "A Single Nucleotide Variant in the Promoter Region of 17β-HSD Type 5 Gene Influences External Genitalia Virilization in Females with 21-Hydroxylase Deficiency. ". Horm Res Paediatr. 2016. PMID 27082632.
  • "Instability of C154Y variant of aldo-keto reductase 1C3. ". Chem Biol Interact. 2017. PMID 28025170.
  • "Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?". BMC Urol. 2016. PMID 27485119.
  • "Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.". Pharmacogenet Genomics. 2016. PMID 27111237.

Cyfeiriadau[golygu | golygu cod y dudalen]